3D Medicines Inc HKEX:1244:
ENVAFOIMAB GRANTED ORPHAN DRUG DESIGNATION
DESIGNATION FOR TREATMENT OF GASTRIC CANCER AND - GASTRO-ESOPHAGEAL JUNCTION CANCER INDICATIONS BY CHINA NMPA
3D Medicines Says Envafoimab Granted Orphan Drug Designation
Later from 3D Medicines
- 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
- 3D Medicines Inc Says Zhang Jing Resigns As CFO
- 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
- Discloseable transaction
- Interim Report 2026
Follow 3D Medicines into a list and get an email when it puts out news.
Follow 3D Medicines